SEC Form EFFECT filed by Conduit Pharmaceuticals Inc.
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | November 1, 2024 4:30 P.M. |
Form: | S-3 | ||||||
|
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | November 1, 2024 4:30 P.M. |
Form: | S-3 | ||||||
|
Save time and jump to the most important pieces.
SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
SC 13G - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)
SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), today announced the restructuring of a portion of its financial obligations, enhancing its balance sheet and liquidity. The Company has restructured the $2.65 million loan note with Nirland Limited ("Nirland") and secured $1.2 million in new promissory notes through separate agreements with third parties. Conduit entered into a $2.65 million loan note with Nirland on August 6, 2024, which was subject to (i) a mandatory 75% repayment clause on new funding, and (ii) a right of first refusal for Nirland on any future fundraising. Conduit and Nirland have re-negotiat
SAN DIEGO and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), today announced it will be participating in the H.C. Wainwright 26th Annual Global Investment Conference, being held September 9-11, 2024. Dr. David Tapolczay, Founder and CEO of Conduit, will give a virtual presentation available on-demand starting on September 9th at 7:00 am ET/12:00 pm BST. Dr. Tapolczay will also be available for in-person, one-on-one investor meetings throughout the conference being held at Lotte New York Palace Hotel, 455 Madison Avenue, New York City. To view Dr. Tapolczay's presentation, please use the following link to register via H.C.
Conduit Pharmaceuticals announces plans to initiate Phase 2a trials in both systemic lupus erythematosus and ANCA-associated vasculitis for its lead clinical candidate, AZD1656AZD1656, a HK-4 glucokinase activator initially developed by AstraZeneca for diabetes, is now being repurposed by Conduit for autoimmune disorders, leveraging its established safety profile and targeted immune-modulating effects SAN DIEGO and LONDON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), today announced the selection of initial indications for its lead clinical candidate, HK-4 glucokinase activator AZD1656 licensed from AstraZeneca on August 7, 20
SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) (the "Company" or "Conduit"), today announced the Company is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on Friday, May 24th, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automat
Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit's commitment to strengthening and broadening its intellectual property portfolio through solid-form technology to maximize future value SAN DIEGO and LONDON, March 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced the appointment of Dr. Joanne Holland as Chief Scientific Officer. Dr. Holland brings over 20 years of experience to the CSO role at Conduit, having amassed expertise across the entire development spectrum. This includes a deep knowledge base in ide
SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), today announced the restructuring of a portion of its financial obligations, enhancing its balance sheet and liquidity. The Company has restructured the $2.65 million loan note with Nirland Limited ("Nirland") and secured $1.2 million in new promissory notes through separate agreements with third parties. Conduit entered into a $2.65 million loan note with Nirland on August 6, 2024, which was subject to (i) a mandatory 75% repayment clause on new funding, and (ii) a right of first refusal for Nirland on any future fundraising. Conduit and Nirland have re-negotiat
Conduit Pharmaceuticals announces plans to initiate Phase 2a trials in both systemic lupus erythematosus and ANCA-associated vasculitis for its lead clinical candidate, AZD1656AZD1656, a HK-4 glucokinase activator initially developed by AstraZeneca for diabetes, is now being repurposed by Conduit for autoimmune disorders, leveraging its established safety profile and targeted immune-modulating effects SAN DIEGO and LONDON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), today announced the selection of initial indications for its lead clinical candidate, HK-4 glucokinase activator AZD1656 licensed from AstraZeneca on August 7, 20
Conduit Pharmaceuticals enters into exclusive license agreement with AstraZeneca for HK-4 Glucokinase activators AZD1656 and AZD5658 targeting autoimmune indications and myeloperoxidase inhibitor AZD5904 targeting idiopathic male infertilityAssets have shown favorable preclinical and Phase I data. Conduit to initiate Phase II clinical trials SAN DIEGO and LONDON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), today announced that the Company has entered into an agreement with AstraZeneca to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase activators, and AZD5904, a myeloperoxidase inhibitor (MPO
424B5 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)
424B3 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)
EFFECT - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)
Shares of Bloom Energy Corporation (NYSE:BE) rose sharply in today's pre-market trading after the company announced a strategic partnership with CoreWeave. Bloom Energy said it entered into a partnership to deploy its proprietary fuel cells to generate on-site power for CoreWeave at a high-performance data center in Illinois. Bloom Energy shares jumped 12.1% to $16.90 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Shimmick Corporation (NASDAQ:SHIM) gained 53% to $3.09 in pre-market trading after the company received a $27.6 million subcontract for the Sunol Valley Water Treatment Plant Ozonation Project. Aptevo Therapeutics Inc. (NA
Conduit Pharmaceuticals Inc (NASDAQ:CDT) shares traded higher by as much as 57% to $0.37 during Tuesday’s session before closing near flat after the company announced it received patent approval for its lead asset targeting autoimmune diseases. The company said this achievement allowed Conduit to participate in the Patent Prosecution Highway (PPH), expediting patent examination in key markets like the U.S., Europe and Japan. Conduit also said the patent, numbered 2022384750, enhanced the likelihood of approvals in other major jurisdictions, providing up to 20 years of protection crucial for drug products. Conduit’s research also identified cocrystals of AZD1656, leveraging solid-fo
Shares of The Charles Schwab Corporation (NYSE:SCHW) fell sharply during Tuesday's session following second-quarter results. Charles Schwab said adjusted net income declined 2% Y/Y to $1.465 billion. Adjusted EPS fell 3% Y/Y to 73 cents, beating the consensus of 72 cents, according to data from Benzinga Pro. Charles Schwab shares dipped 7.5% to $69.42 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Yoshitsu Co., Ltd (NASDAQ:TKLF) jumped 109% to $0.6437 after the company reported a year-over-year increase in FY24 financial results. Silo Pharma, Inc. (NASDAQ:SILO) shares climbed 95.4% to $2.12 after the company obtained an exclusive global l